Literature DB >> 20590607

Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.

S Oger1, D Behr-Roussel, D Gorny, T Lebret, P Validire, X Cathelineau, L Alexandre, F Giuliano.   

Abstract

BACKGROUND AND
PURPOSE: The mechanism(s) of action responsible for the beneficial effects of phosphodiesterase 5 (PDE5) inhibitors including sildenafil on lower urinary tract symptoms suggestive of benign prostate hyperplasia are unclear. In particular, the role of the NO-cGMP signalling pathway in regulating human bladder dome smooth muscle relaxation is questionable. Thus, we assessed the ability of a PDE5 inhibitor, sildenafil, to relax such tissue, and identified the signalling pathways involved in this relaxation. EXPERIMENTAL APPROACH: Human bladder samples were obtained from 20 patients with no overactive bladder undergoing cystectomy for bladder cancer. Detrusor strips were mounted isometrically in Krebs-HEPES solution. Concentration-response curves for sildenafil (10 nM-30 microM) were generated in the presence of various inhibitors on carbachol-induced pre-contraction. KEY
RESULTS: Sildenafil relaxed carbachol-pre-contracted human detrusor strips, starting at 3 microM. This effect was not modified by NO donors, S-nitroso-N-acetylpenicillamine (10 microM) or sodium nitroprusside (300 nM), but was significantly inhibited by inhibition of guanylate cyclase (with ODQ, 10 microM) or adenylyl cyclase (with MDL-12,330A, 10 microM), by the ATP-sensitive potassium channel inhibitor, glibenclamide (10 microM), or inhibition of the large (with iberiotoxin, 30 nM) or small (with apamin, 100 nM) conductance calcium-activated potassium channels. CONCLUSIONS AND IMPLICATIONS: Sildenafil-induced relaxation of human detrusor smooth muscle involved cGMP-, cAMP- and K(+) channel-dependent signalling pathways, with a minor contribution from NO. The effect of this sildenafil-induced relaxation on the clinical benefit of PDE5 inhibitors on urinary storage symptoms in men deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590607      PMCID: PMC2936023          DOI: 10.1111/j.1476-5381.2010.00748.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction.

Authors:  George J Christ; Steve Hodges
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 2.  Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?

Authors:  Petter Hedlund
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

3.  Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.

Authors:  Hanna Tinel; Beatrix Stelte-Ludwig; Joachim Hütter; Peter Sandner
Journal:  BJU Int       Date:  2006-09-06       Impact factor: 5.588

4.  Ca2+-activated K+ (KCa) channels are involved in the relaxations elicited by sildenafil in penile resistance arteries.

Authors:  Dolores Prieto; Luis Rivera; Sara Benedito; Paz Recio; Nuria Villalba; Medardo Hernández; Albino García-Sacristán
Journal:  Eur J Pharmacol       Date:  2006-01-27       Impact factor: 4.432

5.  Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization.

Authors:  M C Truss; S Uckert; C G Stief; M Kuczyk; U Jonas
Journal:  Urol Res       Date:  1996

6.  Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder.

Authors:  L A Birder; G Apodaca; W C De Groat; A J Kanai
Journal:  Am J Physiol       Date:  1998-08

7.  Nitric oxide and relaxation of pig lower urinary tract.

Authors:  K Persson; K E Andersson
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 8.  Potency, selectivity, and consequences of nonselectivity of PDE inhibition.

Authors:  E Bischoff
Journal:  Int J Impot Res       Date:  2004-06       Impact factor: 2.896

9.  Role of nitric oxide in the relaxation elicited by sildenafil in penile resistance arteries.

Authors:  Dolores Prieto; Luis Rivera; Paz Recio; José Luis Ruiz Rubio; Medardo Hernández; Albino García-Sacristán
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

10.  Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

Authors:  Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

View more
  26 in total

Review 1.  The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health.

Authors:  Hanson Zhao; Howard H Kim
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

Review 2.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 3.  PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.

Authors:  K-E Andersson
Journal:  Br J Pharmacol       Date:  2018-04-25       Impact factor: 8.739

Review 4.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

5.  Sildenafil reduces neuroinflammation in cerebellum, restores GABAergic tone, and improves motor in-coordination in rats with hepatic encephalopathy.

Authors:  Ana Agusti; Vicente Hernández-Rabaza; Tiziano Balzano; Lucas Taoro-Gonzalez; Andrea Ibañez-Grau; Andrea Cabrera-Pastor; Santos Fustero; Marta Llansola; Carmina Montoliu; Vicente Felipo
Journal:  CNS Neurosci Ther       Date:  2017-03-11       Impact factor: 5.243

6.  Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.

Authors:  Iraj Mirzaii-Dizgah; Bahram Salmanyan
Journal:  Eur Spine J       Date:  2013-08-02       Impact factor: 3.134

Review 7.  Combination and Novel Pharmacologic Agents for OAB.

Authors:  Whitney Clearwater; Farzaan Kassam; Arshia Aalami Harandi; Christopher F Tenggardjaja; Nitya Abraham
Journal:  Curr Urol Rep       Date:  2022-05-14       Impact factor: 3.092

Review 8.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 9.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

10.  A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms.

Authors:  Mohamed Tharwat; Mohamed M Elsaadany; Ahmed M Lashin; Ahmed R El-Nahas
Journal:  World J Urol       Date:  2018-05-15       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.